Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
about
Update on treatment of light chain amyloidosisTreatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusLong-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Light chain amyloidosis 2012: a new era.Clinical presentation and treatment responses in IgM-related AL amyloidosis.
P2860
Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Treatment of IgM-associated AL ...... bortezomib, and dexamethasone.
@en
Treatment of IgM-associated AL ...... bortezomib, and dexamethasone.
@nl
type
label
Treatment of IgM-associated AL ...... bortezomib, and dexamethasone.
@en
Treatment of IgM-associated AL ...... bortezomib, and dexamethasone.
@nl
prefLabel
Treatment of IgM-associated AL ...... bortezomib, and dexamethasone.
@en
Treatment of IgM-associated AL ...... bortezomib, and dexamethasone.
@nl
P50
P356
P1476
Treatment of IgM-associated AL ...... bortezomib, and dexamethasone
@en
P2093
Andrea Foli
Paola Russo
P304
P356
10.3816/CLML.2011.N.033
P407
P577
2011-02-01T00:00:00Z